Last December, when U.S. Food and Drug Administration advisers met to determine whether the agency should authorize Pfizer's Covid-19 vaccine, it was generally understood that the answer would be yes. Nine months later, these advisers meet to discuss the booster injections, and the situation is very different. It won't be a slam dunk. When this advisory board meets on Friday, it will be presented with dueling data, some sarguing that there is a need for boosters, but other data suggests that there is no such need. Advisors will also likely debate the very essence of Covid-19 boosters - whether they would work and what they even are supposed to accomplish in the first place. Read more It will be much more complicated than in December said Dr William Schaffner, infectious disease specialist at Vanderbilt University. Schaffner has been following the FDA deliberations closely, as he is a member of an advisory committee of the United States Centers for Disease Control and Prevention that will review the booster injections if the FDA gives the green light to Pfizer's request. . Schaffner added that the action of the Biden administration had surprised doctors and scientists. compared it to when President Donald Trump last year pronounced certain approaches, such as the drug hydroxychloroquine, as treatments for Covid-19 even though no studies had been done. What Trump did profoun People are not upset at all, Schaffner said, and something like this was not expected to happen in the current administration. Rubin, Harvard 's infectious disease expert and FDA vaccine adviser, said he would win ' No matter for him and his colleaguesThat's what Biden said. I think it's really important to point out that neither of us work directly for the president, and what the president says doesn't really affect our vote on the committee, Rubin said. I feel it very strongly.